<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39456976</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Subduing the Inflammatory Cytokine Storm.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11194</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms252011194</ELocationID><Abstract><AbstractText>The inflammatory cytokine response is essential for protective immunity, yet bacterial and viral pathogens often elicit an exaggerated response ("cytokine storm") harmful to the host that can cause multi-organ damage and lethality. Much has been published recently on the cytokine storm within the context of the coronavirus pandemic, yet bacterial sepsis, severe wound infections and toxic shock provide other prominent examples. The problem of the cytokine storm is compounded by the increasing incidence of multidrug-resistant bacterial strains. We created an incisive molecular tool for analyzing the role of the B7/CD28 costimulatory axis in the human inflammatory response. To attenuate the cytokine storm underlying infection pathology, yet preserve host defenses, we uniquely targeted the engagement of CD28 with its B7 co-ligands by means of short peptide mimetics of the human CD28 and B7 receptor homodimer interfaces. These peptides are not only effective tools for dissecting mechanism but also serve to attenuate the inflammatory response as a broad host-oriented therapeutic strategy against the cytokine storm. Indeed, such peptides protect mice from lethal Gram-positive bacterial superantigen-induced toxic shock even when dosed in molar amounts well below that of the superantigen and show promise in protecting humans from the severe inflammatory disease necrotizing soft tissue infections ('flesh-eating' bacterial sepsis) following traumatic wound injuries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaempfer</LastName><ForeName>Raymond</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5865-4619</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018089">Superantigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="Y">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018089" MajorTopicYN="N">Superantigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B7</Keyword><Keyword MajorTopicYN="N">CD28</Keyword><Keyword MajorTopicYN="N">costimulatory receptor</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">homodimer interface</Keyword><Keyword MajorTopicYN="N">immune costimulation</Keyword><Keyword MajorTopicYN="N">inflammatory cytokines</Keyword><Keyword MajorTopicYN="N">lethal toxic shock</Keyword><Keyword MajorTopicYN="N">mimetic peptides</Keyword></KeywordList><CoiStatement>R.K. is an inventor of patents for the peptides described.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39456976</ArticleId><ArticleId IdType="pmc">PMC11508503</ArticleId><ArticleId IdType="doi">10.3390/ijms252011194</ArticleId><ArticleId IdType="pii">ijms252011194</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fajgenbaum D.C., June C.H. Cytokine storm. N. Engl. J. Med. 2020;383:2255–2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Huang S., Yin L. The cytokine storm and COVID-19. J. Med. Virol. 2021;93:250–256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabler S.S., French A.R., Orvedahl A. A cytokine circus with a viral ringleader: SARS-CoV-2-associated cytokine storm syndromes. Trends Mol. Med. 2020;26:1078–1085. doi: 10.1016/j.molmed.2020.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2020.09.012</ArticleId><ArticleId IdType="pmc">PMC7524648</ArticleId><ArticleId IdType="pubmed">33051104</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman A., Kappler J.W., Marrack P., Pullen A.M. Superantigens: Mechanisms of T-cell stimulation and role in immune responses. Ann. Rev. Immunol. 1991;9:745–772. doi: 10.1146/annurev.iy.09.040191.003525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.iy.09.040191.003525</ArticleId><ArticleId IdType="pubmed">1832875</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlievert P.M. Role of superantigens in human disease. J. Infect. Dis. 1993;167:997–1002. doi: 10.1093/infdis/167.5.997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/167.5.997</ArticleId><ArticleId IdType="pubmed">8486972</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohach G.A., Fast D.J., Nelson R.D., Schlievert P.M. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit. Rev. Microbiol. 1990;17:251–272. doi: 10.3109/10408419009105728.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10408419009105728</ArticleId><ArticleId IdType="pubmed">2206394</ArticleId></ArticleIdList></Reference><Reference><Citation>Efrat S., Pilo S., Kaempfer R. Kinetics of induction and molecular size of mRNA species encoding human interleukin-2 and gamma-interferon. Nature. 1982;297:236–239. doi: 10.1038/297236a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/297236a0</ArticleId><ArticleId IdType="pubmed">6176875</ArticleId></ArticleIdList></Reference><Reference><Citation>Efrat S., Kaempfer R. Control of biologically active interleukin-2 messenger RNA formation in induced human lymphocytes. Proc. Natl. Acad. Sci. USA. 1984;81:2601–2605. doi: 10.1073/pnas.81.9.2601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.81.9.2601</ArticleId><ArticleId IdType="pmc">PMC345117</ArticleId><ArticleId IdType="pubmed">6609365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebendiker M.A., Tal C., Sayar D., Pilo S., Eilon A., Banai Y., Kaempfer R. Superinduction of the human gene encoding immune interferon. EMBO J. 1987;6:585–589. doi: 10.1002/j.1460-2075.1987.tb04794.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1987.tb04794.x</ArticleId><ArticleId IdType="pmc">PMC553437</ArticleId><ArticleId IdType="pubmed">3107985</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerez L., Madar L., Arad G., Sharav T., Reshef A., Ketzinel M., Sayar D., Silberberg C., Kaempfer R. Aberrant regulation of interleukin-2 but not of interferon-gamma gene expression in Down Syndrome (trisomy 21) Clin. Immunol. Immunopathol. 1991;58:251–266. doi: 10.1016/0090-1229(91)90140-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-1229(91)90140-6</ArticleId><ArticleId IdType="pubmed">1824688</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerez L., Madar L., Shkolnik T., Kristal B., Arad G., Reshef A., Steinberger A., Ketzinel M., Sayar D., Shasha S., et al. Regulation of interleukin-2 and interferon-gamma gene expression in renal failure. Kidney Int. 1991;40:266–272. doi: 10.1038/ki.1991.209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1991.209</ArticleId><ArticleId IdType="pubmed">1942774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaempfer R., Gerez L., Farbstein H., Madar L., Hirschman O., Nussinovich R., Shapiro A. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J. Clin. Oncol. 1996;14:1778–1786. doi: 10.1200/JCO.1996.14.6.1778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.1996.14.6.1778</ArticleId><ArticleId IdType="pubmed">8656246</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerez L., Shkolnik T., Hirschmann O., Lorber M., Arad G., Kaempfer R. Hyperinducible expression of the interferon-gamma (IFN-gamma) gene and its suppression in Systemic Lupus Erythematosus (SLE) Clin. Exp. Immunol. 1997;109:296–303. doi: 10.1046/j.1365-2249.1997.4471345.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1997.4471345.x</ArticleId><ArticleId IdType="pmc">PMC1904755</ArticleId><ArticleId IdType="pubmed">9276525</ArticleId></ArticleIdList></Reference><Reference><Citation>Arad G., Levy R., Hillman D., Kaempfer R. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat. Med. 2000;6:414–421. doi: 10.1038/74672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/74672</ArticleId><ArticleId IdType="pubmed">10742148</ArticleId></ArticleIdList></Reference><Reference><Citation>Arad G., Levy R., Nasie I., Hillman D., Rotfogel Z., Barash U., Supper E., Shpilka T., Minis A., Kaempfer R. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate shock. PLoS Biol. 2011;9:e1001149. doi: 10.1371/journal.pbio.1001149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1001149</ArticleId><ArticleId IdType="pmc">PMC3172200</ArticleId><ArticleId IdType="pubmed">21931534</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy R., Rotfogel Z., Hillman D., Popugailo A., Arad G., Supper E., Osman F., Kaempfer R. Superantigens hyperinduce inflammatory cytokines by enhancing the B7-2/CD28 costimulatory receptor interaction. Proc. Natl. Acad. Sci. USA. 2016;113:E6437–E6446. doi: 10.1073/pnas.1603321113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1603321113</ArticleId><ArticleId IdType="pmc">PMC5081635</ArticleId><ArticleId IdType="pubmed">27708164</ArticleId></ArticleIdList></Reference><Reference><Citation>Popugailo A., Rotfogel Z., Supper E., Hillman D., Kaempfer R. Staphylococcal and streptococcal superantigens trigger B7/CD28 costimulatory receptor engagement to hyperinduce inflammatory cytokines. Front. Immunol. 2019;10:942. doi: 10.3389/fimmu.2019.00942.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00942</ArticleId><ArticleId IdType="pmc">PMC6503043</ArticleId><ArticleId IdType="pubmed">31114583</ArticleId></ArticleIdList></Reference><Reference><Citation>Popugailo A., Rotfogel Z., Hillman D., Levy M., Turgeman O., Levy R., Arad G., Shpilka T., Kaempfer R. The homodimer interfaces of costimulatory receptors B7 and CD28 control their engagement and pro-inflammatory signaling. J. Biomed. Sci. 2023;30:49. doi: 10.1186/s12929-023-00941-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-023-00941-3</ArticleId><ArticleId IdType="pmc">PMC10308680</ArticleId><ArticleId IdType="pubmed">37381064</ArticleId></ArticleIdList></Reference><Reference><Citation>Earhart C.A., Mitchell D.T., Murray D.L., Pinheiro D.M., Matsumura M., Schlievert P.M., Ohlendorf D.H. Structures of five mutants of toxic shock syndrome toxin-1 with reduced biological activity. Biochemistry. 1998;37:7194–7202. doi: 10.1021/bi9721896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi9721896</ArticleId><ArticleId IdType="pubmed">9585531</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson C.B., Lindsten T., Ledbetter J.A., Kunkel S.L., Young H.A., Emerson S.G., Leiden J.M., June C.H. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA. 1989;86:1333–1337. doi: 10.1073/pnas.86.4.1333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.86.4.1333</ArticleId><ArticleId IdType="pmc">PMC286684</ArticleId><ArticleId IdType="pubmed">2465550</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans E.J., Esnouf R.M., Manso-Sancho R., Gilbert R.J., James J.R., Yu C., Fennelly J.A., Vowles C., Hanke T., Walse B., et al. Crystal structure of a soluble CD28-Fab complex. Nat. Immunol. 2005;6:271–279. doi: 10.1038/ni1170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1170</ArticleId><ArticleId IdType="pubmed">15696168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikemizu S., Gilbert R.J., Fennelly J.A., Collins A.V., Harlos K., Jones E.Y., Stuart D.I., Davis S.J. Structure and dimerization of a soluble form of B7-1. Immunity. 2000;12:51–60. doi: 10.1016/S1074-7613(00)80158-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)80158-2</ArticleId><ArticleId IdType="pubmed">10661405</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz J.C., Zhang X., Fedorov A.A., Nathenson S.G., Almo S.C. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature. 2001;410:604–608. doi: 10.1038/35069112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35069112</ArticleId><ArticleId IdType="pubmed">11279501</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamper C.C., Zhang Y., Tobin J.F., Erbe D.V., Ikemizu S., Davis S.J., Stahl M.L., Seehra J., Somers W.S., Mosyak L. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature. 2001;410:608–611. doi: 10.1038/35069118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35069118</ArticleId><ArticleId IdType="pubmed">11279502</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S.J., Ikemizu S., Evans E.J., Fugger L., Bakker T.R., van der Merwe P.A. The nature of molecular recognition by T cells. Nat. Immunol. 2003;4:217–224. doi: 10.1038/ni0303-217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni0303-217</ArticleId><ArticleId IdType="pubmed">12605231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran G., Tulapurkar M.E., Harris K.M., Arad G., Shirvan A., Shemesh R., DeTolla L.J., Benazzi C., Opal S.M., Kaempfer R., et al. A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft tissue infection induced by Streptococcus pyogenes. J. Infect. Dis. 2013;207:1869–1877. doi: 10.1093/infdis/jit104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit104</ArticleId><ArticleId IdType="pmc">PMC3654752</ArticleId><ArticleId IdType="pubmed">23493729</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran G., Kaempfer R., Chung C.-S., Chahin A.B., Palardy J.E., Parejo N.A., Chen Y., Whitford M., Arad G., Hillman D., et al. CD28 homodimer interface mimetic peptide acts as preventive and therapeutic agent in models of severe bacterial sepsis and Gram-negative bacterial peritonitis. J. Infect. Dis. 2015;211:995–1003. doi: 10.1093/infdis/jiu556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu556</ArticleId><ArticleId IdType="pmc">PMC4416127</ArticleId><ArticleId IdType="pubmed">25305323</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzoeva S., Paunesku T., Wanzer M.B., Shirvan A., Kaempfer R., Woloschak G.E., Small W., Jr. Single administration of p2TA (AB103), a CD28 antagonist peptide, prevents inflammatory and thrombotic reactions and protects against gastrointestinal injury in total-body irradiated mice. PLoS ONE. 2014;9:e101161. doi: 10.1371/journal.pone.0101161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0101161</ArticleId><ArticleId IdType="pmc">PMC4108308</ArticleId><ArticleId IdType="pubmed">25054224</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger E.M., Maier R.V., Sperry J., Joshi M., Henry S., Moore F.A., Moldawer L.L., Demetriades D., Talving P., Schreiber M., et al. A novel drug for treatment of necrotizing soft-tissue infections: A randomized clinical trial. JAMA Surg. 2014;149:528–536. doi: 10.1001/jamasurg.2013.4841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2013.4841</ArticleId><ArticleId IdType="pubmed">24740134</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger E.M., May A.K., Robinson B.R.H., Evans D.C., Henry S., Green J.M., Toschlog E., Sperry J.L., Fagenholz P., Martin N.D., et al. A novel immune modulator for patients with necrotizing soft tissue infections (NSTI). Results of a multicenter, phase 3 randomized controlled trial of reltecimod (AB 103) Ann. Surg. 2020;272:469–478. doi: 10.1097/SLA.0000000000004102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000004102</ArticleId><ArticleId IdType="pubmed">32657946</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Chen H., Xu C., Hu M., Li J., Chang W. Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention. Front. Immunol. 2024;15:1422591. doi: 10.3389/fimmu.2024.1422591.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1422591</ArticleId><ArticleId IdType="pmc">PMC11381299</ArticleId><ArticleId IdType="pubmed">39253080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandström K., Xu Z., Forsberg G., Nygren P.-Å. Inhibition of the CD28—CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering. Protein Eng. Des. Sel. 2003;16:691–697. doi: 10.1093/protein/gzg086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/gzg086</ArticleId><ArticleId IdType="pubmed">14560055</ArticleId></ArticleIdList></Reference><Reference><Citation>Heninger A.K., Wentrup S., Al-Saeedi M., Schiessling S., Giese T., Wartha F., Meuer S., Schröder-Braunstein J. Immunomodulation of human intestinal T cells by the synthetic CD80 antagonist RhuDex®. Immun. Inflamm. Dis. 2014;2:166–180. doi: 10.1002/iid3.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.34</ArticleId><ArticleId IdType="pmc">PMC4257762</ArticleId><ArticleId IdType="pubmed">25505551</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong G.C., Chuang P.H., Chang K.C., Jan P.S., Hwang P.I., Wu H.B., Yi M., Zhou H.X., Chen H.M. Blocking effect of an immuno-suppressive agent, cynarin, on CD28 of T-cell receptor. Pharm. Res. 2009;26:375–381. doi: 10.1007/s11095-008-9754-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-008-9754-5</ArticleId><ArticleId IdType="pmc">PMC2701378</ArticleId><ArticleId IdType="pubmed">18989760</ArticleId></ArticleIdList></Reference><Reference><Citation>Green N.J., Xiang J., Chen J., Chen L., Davies A.M., Erbe D., Tam S., Tobin J.F. Structure-activity studies of a series of dipyrazolo [3,4-b:3′,4′-d]pyridin-3-ones binding to the immune regulatory protein B7.1. Bioorg. Med. Chem. 2003;11:2991–3013. doi: 10.1016/S0968-0896(03)00183-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0968-0896(03)00183-4</ArticleId><ArticleId IdType="pubmed">12788368</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>